[ad_1]
Pfizer hopes to be able to distribute 50 million doses of the coronavirus vaccine it has developed by 2020, instead of the 100 million doses it had budgeted for, due to problems in the supply chain for its production. vaccine, broadcast on the Dow Jones network.
However, the company continues to estimate that it will produce more than 1 billion doses by 2021.
“The escalation of the raw materials supply chain has been delayed more than we expected,” said a spokeswoman for the company. “And it is important to note that the results of the clinical trials of the vaccine also came somewhat later than expected,” he added.
Pfizer and Germany-based BioNTech expected to be able to distribute 100 million doses worldwide by the end of the year, a plan that was cut to 50 million doses. Britain on Wednesday granted emergency approval to the drug and thus became the first Western country to start vaccinations, likely within the next week.
The vaccine, which is administered in two doses, is already under consideration by authorities in the US and the European Union and is expected to be approved by regulators in the US and the EU in December.
Then it will be the turn of the Modern American vaccine.
“We were late,” said a person directly involved in the development of the Pfizer vaccine. “Some commodities did not meet the criteria. We fixed it, but we lost time and we are no longer catching up with the distributions that we were budgeting for 2020,” he added, according to Dow Jones.
The effectiveness of the vaccine reaches 95%, according to the third phase of clinical trials, in 44,000 volunteers.
Pfizer supplies its raw materials from the US and Europe, but did not elaborate on exactly what the problem was and with what material.
By 2021, Pfizer and BioNtech estimate to produce and distribute 1.3 billion doses of their vaccine, part of which will cover the 50 million “lost” by 2020.
Britain has ordered 40 million doses, enough to vaccinate 20 million people.
The United States has requested 100 million quotas, with the possibility of requesting another 500 million.
The EU has asked for 200 million quotas, with the possibility of asking for another 100 million.
Japan has requested 120 million doses.
